Articles tagged with Molecular Targets
Researchers uncover critical shape-change in cereblon protein that CELMoD drugs must cause to work effectively. The finding enables the development of more effective cancer-fighting treatments.
Researchers found that reducing SAMHD1 levels made brain tumor cells sensitive to chemotherapy drugs and slowed cell growth. They also suspect that glioblastoma alters SAMHD1's function to aid its own survival and treatment resistance.
In the ARROS-1 trial, 48% of patients achieved partial responses to NVL-520, with responses seen across all dose levels and in heavily pre-treated patients. The treatment also showed promise for brain metastases, with three out of three patients experiencing measurable response or no emergence of new metastases.
Researchers at Kyoto University have developed a prodrug form of curcumin called TBP1901, which has shown anti-tumor effects without causing harm. The study found that TBP1901's conversion to active curcumin is dependent on the enzyme GUSB, suggesting its potential therapeutic targets.
A Phase Ib clinical trial found that sequential administration of PARP inhibitor olaparib and WEE1 inhibitor adavosertib is safe and well-tolerated, with promising signs of anti-tumor activity in patients with advanced cancers driven by DNA damage response mutations. The combination showed durable responses in patients with resistant c...
A new experimental drug has shown promising results in treating liver cancer, with two patients experiencing a partial response to the treatment. The drug, NMS-01940153E, targets an enzyme that plays a critical role in cell division and growth, and its side effects are manageable.
The study found that BRAF alterations, particularly Class I mutations like v600E, are associated with improved overall survival in adults with glioma. However, the effectiveness of targeted therapies depends on the specific type and combination of genetic alterations driving the cancer.
A study published in Science Advances reveals that physical exercise triggers a neuromuscular circuit that links the production of interleukin-6 to muscle fat breakdown. This circuit is crucial for weight loss and has significant implications for obesity treatment.
Researchers at La Jolla Institute for Immunology have developed a new therapy for Lassa fever using a trio of rare human antibodies that can block viral infection. The therapy, called Arevirumab-3, was tested in non-human primates and proved 100% effective in treating the disease.
The NCI-MATCH precision medicine cancer trial found a promising signal for the AKT inhibitor ipatasertib, meeting its primary endpoint with a 22% response rate in patients with rare AKT1 E17K tumor gene mutations. The study demonstrated clinically significant activity in patients, warranting additional studies.
Researchers have found a drug that targets the key, cancer-causing gene MYC has been able to inhibit its function safely and effectively. Eight out of 12 patients showed stabilisation of disease after treatment with OMO-103, with one patient experiencing a reduction in tumour-derived DNA circulating in the blood stream.
A new approach combines an immunotherapy agent with a molecular delivery system that targets tumor acidity, successfully eradicating colorectal tumors in mice. The researchers believe this method may increase the effectiveness of STING agonist therapy for cancer patients.
Researchers have designed a potential therapeutic that dampens the activity of regulatory T cells, which can prevent the immune system from unleashing its full potential against tumor cells. The molecule, known as FOX3P, acts as a transcription factor for many Treg genes but isn't vital for other types of T cells.
Researchers identified a kinase molecule that directs microglia activity, potentially treating neurodegenerative diseases like Alzheimer's and MS. The molecule, called spleen tyrosine kinase, targets plaque buildup and debris accumulation in the brain.
The study analyzed DNA methylation in skin tumor samples, revealing correlations between changes in proteins regulating the organism and prognosis. The results identified potential markers of patient survival and suggested a new route for understanding melanoma subtypes.
Researchers found that metformin targeted 30 genes associated with atrial fibrillation, showing direct effects on gene expression for eight. The study suggests metformin may be a promising candidate for treating atrial fibrillation due to its potential to reduce the risk of complications such as stroke and heart failure.
A Cleveland Clinic-led research team created a discovery tool outlining interactions between COVID-19 and host proteins, identifying potential host-targeting therapies. The study confirmed over 200 interactions and discovered new ones, highlighting promising approaches for treating COVID-19.
A new study reveals that different SCLC subtypes have specific molecular characteristics, leading to varying responses to cancer treatment. The research provides a basis for developing targeted and personalized treatment approaches tailored to each subtype.
Scientists at Northwestern University have identified a new gene that activates an aggressive subtype of small-cell lung cancer with no current effective treatment. Deleting this gene kills cancer cells in deadly subtype.
Researchers used multi-omics technologies to analyze samples from 350 patients with major depressive disorder, finding distinct blood-based signatures between those with and without a history of attempted suicide. Variations in genes CLOCK and ARNTL were associated with lower antidepressant response rates.
A novel PET radiotracer has been developed to assess tumor aggressiveness in neuroendocrine neoplasms, providing valuable information for personalized care. High uPAR expression was associated with a worse prognosis, making it a potential target for therapy.
Researchers at the University of Arizona have identified a protein called Ait1 that regulates cell growth in yeasts. This discovery presents new targets for developing antifungal drugs that can attack disease-causing yeasts while sparing human immune cells.
Researchers have identified a small molecule drug, SHP656, that can target the circadian clock proteins responsible for glioblastoma's recurrence and spread. The drug has shown promise in reducing cancer stem cell growth without harming normal stem cells.
Scientists developed a laser-based zebrafish model to simulate traumatic brain injuries and identify molecular targets for treatment. The model revealed the importance of microglia activation and brain-derived neurotrophic factor (BDNF) in brain recovery.
Researchers at the University of Pittsburgh have identified a universal mechanism for lysosomal repair, known as the PITT pathway, which helps maintain cellular longevity. The study reveals that damaged lysosomes are quickly repaired through the PITT pathway, but defects in this process can contribute to age-related diseases such as Al...
The report explores diffuse optical imaging methods applicable to noninvasive human studies, including near-infrared spectroscopy (NIRS) and diffuse correlation spectroscopy (DCS). It introduces state-of-the-art technologies and software, exploring their impact on neuroscience and clinical applications.
A new study suggests that the nuclear receptor TLX can inhibit the growth and progression of triple-negative breast cancer. TLX+ cells showed lower tumor growth, migration, and invasion rates compared to those without TLX expression.
Scientists have developed a method to control chemical reactions in a single molecule by applying voltage pulses, resulting in unprecedented selectivity. By fine-tuning the voltage, researchers can interconvert different products formed during the reaction.
A new class of light-activated hemithioindigo molecules developed by Rice University scientists kill specific Gram-positive bacteria and their biofilms. The molecules induce reactive oxygen species that chemically attack and destroy drug-resistant cells, offering a safer alternative to conventional antibiotics.
Researchers have discovered a molecule that can suppress the development of kidney fibrosis, a condition leading to kidney failure and devastating consequences. The breakthrough could lead to the development of new drug treatments for millions of people affected by chronic kidney disease.
Researchers developed a new anti-cancer drug LP-182 that simultaneously targets two molecular signaling pathways responsible for cancer growth. The drug is absorbed through the gut's lymphatic system, maintaining optimal therapeutic levels over time.
Researchers analyzed data from over 3,000 participants and found no association between electrocardiogram measures and telomere length. The study suggests that ECG prolongation is age-dependent but not a marker of biological aging.
A new study published in Nature reveals that microglia cells change their molecular state to match neighboring neurons, influencing neural circuit function. The researchers found that different types of cortical neurons recruit specific numbers of microglia, which then adapt to the neuron's environment.
Researchers identified toll-like receptor (TLR) signaling as a novel pathway regulating GLI3 expression, which plays a role in inflammatory cytokine production and cancer. They found that IRF3 directly binds to the GLI3 promoter region, increasing its expression upon TLR4 stimulation.
Researchers have identified key molecular differences between cancer cells that cling to initial tumors and those that spread to distant sites. The study found unique properties in cells that gain migratory ability and survival advantages, leading to the development of new treatment targets.
The NCI-backed Molecular Targets Platform streamlines and catalyzes drug development by integrating pediatric cancer targets and pathways. This platform empowers researchers, pharmaceutical companies, and advocacy groups to accelerate the pace of drug development for pediatric cancer.
The Polyphenols Applications 2022 World Congress will focus on the latest findings and emerging trends in polyphenol research, covering various topics such as microbiota, adipose tissue, nervous system, senolytic activity, ageing, endothelial function, radioprotection, atherosclerosis, and more. Over 300 international participants will...
Researchers identified CUDC907 as a dual phosphoinositide-3 kinase/histone deacetylase inhibitor that promotes apoptosis in NF2 schwannoma cells. The compound reduced viability and induced cell cycle arrest in human merlin deficient Schwann cell models.
Researchers at Arizona State University have discovered molecular signatures associated with acute and chronic phases of traumatic brain injury (TBI). The study aims to address current limitations in TBI diagnosis and treatment by identifying biomarkers and understanding the blood-brain barrier's role in drug delivery.
A novel peptide has been developed for targeted transport of molecules, including active substances and dyes, into mammalian cells. The peptide interacts with an acidic partner peptide to facilitate precise delivery.
Researchers used chemoproteomics to profile 53 HDAC drugs and found many had additional targets beyond their intended HDACs. The study identified MBLAC2 as a common off-target protein that affects extracellular vesicle accumulation.
Rensselaer researchers will use a five-year grant to develop novel inhibitors of the SARS-CoV-2 virus's CLpro and PLpro proteases. The team aims to create an orally bioavailable drug that can be administered at home, with the potential for improved antiviral activity when combined with other drugs like remdesivir.
A study found that a methionine-deficient diet alters gene expression and DNA methylation in liver cells, increasing the risk of non-alcoholic fatty liver disease. A methionine-supplemented diet had the opposite effect, reducing the risk of liver damage.
A novel targeted radionuclide alpha therapy, AC-NM600, has been shown to achieve significantly better outcomes than its corresponding beta therapy in treating metastatic castration-resistant prostate cancer. The study demonstrated slowed tumor growth and improved overall survival.
Researchers have identified three distinct brain circuits in the thalamus that contribute to Parkinson's disease symptoms, including motor dysfunction and depression. By manipulating these circuits, they were able to reverse Parkinson's symptoms in mice, suggesting potential new therapeutic targets.
A molecule in mosquito spit called sialokinin has been identified as a potential new target for vaccination against Yellow Fever, Dengue and Zika. Researchers found that sialokinin causes blood vessels to become permeable, allowing viruses to infect the host.
Researchers found that inhibiting caspase 11 reduced inflammation, tissue injury and blood clots in lung tissue of infected mice. This suggests potential therapeutic targets for treating severe COVID-19 symptoms.
Researchers at Cedars-Sinai have comprehensively mapped molecular activity in the brain and spinal cord that regulates body's response to central nervous system (CNS) disorders. They discovered a critical role of astrocytes, specialized support cells, in regulating outcomes for CNS disorders.
Researchers from Arizona State University investigate autoantibodies in healthy individuals, revealing their pervasiveness and role in human health and disease. The findings aim to improve diagnostics and therapeutics for a range of illnesses.
Researchers at UC Riverside have found that common microbial communities can degrade a stubborn class of PFAS called fluorinated carboxylic acids (FCAs) by breaking the carbon-fluorine bond under anaerobic conditions. This breakthrough could lead to new methods for environmental remediation and reduce the harm caused by PFAS.
Researchers at the Beckman Institute found a direct link between high-fat diets and heightened nitric oxide levels, which can lead to increased risk of inflammation and cancer development. The study used a molecular probe to visualize changes in the tumor microenvironment.
Researchers at University of Missouri, Georgia Tech and Harvard University have successfully demonstrated a new Type 1 diabetes treatment in large animal models. By transplanting pancreatic islet cells with a molecule called FasL, they prevent rogue immune cells from destroying the transplanted cells.
A new study suggests that supplementing a diet with Ascidiacea, also known as sea squirts, reverses some main signs of aging in animal models. The researchers found that plasmalogens, vital to body processes, decrease with age and contribute to neurodegenerative diseases like Alzheimer's and Parkinson's.
A new canine coronavirus variant has been identified in human patients with pneumonia, showing a shift from infecting both the intestines and respiratory system to only the respiratory system. Researchers used state-of-the-art tools to assess evolution pressures that may have influenced this shift.
The joint guide provides a framework for establishing theranostic centers globally, focusing on safety protocols and operational procedures. It highlights best practices for radiation protection, storage, administration, and other topics to improve patient care.
Scientists at Scripps Research developed a new method called CATCH to image where drugs bind to their targets across different tissues and with higher precision than ever before. This technique allows for better understanding of why one drug is more potent or has a particular side effect compared to another.
Researchers at Karolinska Institutet have developed a method to identify the immune cells involved in autoimmune diseases and identified four new target molecules for personalized treatment of multiple sclerosis. This approach could lead to more precise treatments with fewer side effects, potentially benefiting other autoimmune diseases.
Researchers developed a disposable electrochemical sensor using graphite-based molecularly imprinted polymers to detect theophylline levels. The sensor can identify low concentrations of theophylline (2.5 μg/mL) in whole blood within 3 seconds, enabling real-time monitoring and potential overdose prevention.
The new computational tool, AF2Complex, predicts the structure of protein complexes and their interactions, offering insights into biomolecular mechanisms. The model is based on AlphaFold 2 and performs well in predicting protein structures and complex formations.
Researchers at Gladstone Institutes and UC San Francisco have developed a comprehensive rule book for designing therapeutic cells with improved specificity and safety. The new receptor system, dubbed SNIPRs, is small enough for cost-effective engineering into human cells and can detect and respond to even small amounts of its target. T...